

To,

Date: 14.08.2023

1. BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400001

2. National Stock Exchange of India Limited,
Exchange Plaza, Bandra- Kurla Complex,
Mumbai-400051

Dear Sir/Madam,

Sub: Outcome of the Board meeting held on 14.08.2023

Ref: Company's letter dated 04.08.2023

With reference to the subject cited, this is to inform the Exchanges that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Monday, 14.08.2023 at 4:00 p.m. at the registered office of the company at D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street no. 3, Baghlingampally, Hyderabad - 500044 Telangana, the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2023. (Enclosed)
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2023. (Enclosed)



The meeting concluded at 8:30 P.M

This is for the information and records of the Exchanges, please.

Thanking you.

Yours sincerely,

For Ortin Laboratories Limited

S. Murali Krishna Murthy
Managing Director
DIN: 00540632

Encl: as above

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023


(Rs. In Lakhs)

S No	Particulars	Quarter Ended			Year ended	
		30.06.2023	31.03.2023	30.06.2022	31.03.23	31.03.22
		Un Audited	Audited	Un Audited	Audited	Audited
1	a) Net Sales / Income from Operations	157.09	145.65	262.05	602.03	823.08
2	b) Other Operating Income	0.28	2.92	0.14	4.20	19.45
3	Total Income (1+2)	157.37	148.57	262.19	606.23	842.53
4	Expenditure					
	a) Cost of Material Consumed	111.35	43.25	205.45	389.24	460.57
	b) Employee Benefits Expenses	19.16	19.75	21.54	84.66	95.03
	c) changes in inventory	-40.54	47.92	-13.28	-50.27	4.60
	d) Finance cost	11.42	11.70	9.52	39.64	81.06
	e) Depreciation	5.87	3.21	7.34	25.01	29.38
	d) Other Expenditure	48.55	40.89	28.36	126.33	224.89
	e) Total Expenses	155.81	166.72	258.94	614.61	895.52
5	Profit / (Loss) before Exceptional Items and tax (3-4)	1.56	-18.15	3.25	-8.38	-52.99
6	Exceptional Items	0.00	2.67	0.00	2.67	0.00
7	Profit / (Loss) before tax (5-6)	1.56	-20.82	3.25	-11.05	-52.99
8	Tax Expense					0.00
	a) Current Tax	0.00	-0.61	0.00	0.00	0.00
	b) Deferred Tax	-0.08	0.14	45.93	-1.69	-13.12
9	Profit / (Loss) after tax for the period from continuing operations (7-8)	1.64	-20.35	-42.67	-9.36	-39.87
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	1.64	-20.35	-42.67	-9.36	-39.87
12	Paid-up equity share capital (Face value of Rs. 10/- per share)	813.14	813.14	813.14	813.14	813.14
13	Other Equity				273.35	282.54
14	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.02	-0.25	-0.52	-0.12	-0.49
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.02	-0.25	-0.52	-0.12	-0.49


Notes:

- The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14.08.2023 .
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.
- The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.
- The results are also available on the website of the Company www.ortinlabsindia.com & stock exchanges websites at www.bseindia.com & www.nse.com.
- The Drugs Control Administration, Government of Telangana has cancelled the Manufacturing License of the Company as the Company could not upgrade the manufacturing facilities, infrastructure and recruitment of expert technical team as per the provisions of Schedule – M of Drugs & Cosmetics Act-1940 & rules made there under. Hence the Company has stopped the production of medicines in its manufacturing unit.

For and on Behalf of the Board of Directors
ORTIN LABORATORIES LIMITED



S.MURALI KRISHNA MURTHY
Managing Director
(DIN: 00540632)



Place: Hyderabad
Date: 14.08.2023



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on unaudited quarterly and year to date financial results of the Company


**To The Board of Directors of
Ortin Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Laboratories Limited ("the Company") for the quarter ended on 30th June, 2023 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. *The Drugs Control Administration, Government of Telangana has cancelled the Manufacturing License of the Company vide their proceeding dated 03.07.2023 as the Company could not upgrade the manufacturing facilities, infrastructure and recruitment of expert technical team as per the provisions of Schedule - M of Drugs & Cosmetics Act 1940 & rules made there under. Hence the Company has stopped the production of medicines in its manufacturing unit. Our opinion is not modified in respect of this matter.*
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

B. V. RAMANA REDDY
M. No: 026967 Partner



UDIN: 23026967BGUSDM9910

Place: Hyderabad

Date: 14.08.2023

E-mail : mateshca@yahoo.co.in